Nav: Home

Novel drug shows promise against acute myeloid leukemia

April 11, 2018

April 11, 2018--(BRONX, NY)--In a study published online today in Science Translational Medicine, Albert Einstein College of Medicine researchers report that an experimental peptide (small protein) drug shows promise against the often-lethal cancer acute myeloid leukemia (AML) and describe how the drug works at the molecular level. The findings have led to a Phase I/II clinical trial for patients with advanced AML and advanced myelodysplastic syndrome (MDS), now underway at Montefiore Health System.

In preclinical studies, the experimental drug--ALRN-6924--tripled the median survival rate in an animal model of human AML (mice transplanted with human leukemia cells) from 50 to about 150 days.

"This is a very striking response," said study leader Ulrich Steidl, M.D., Ph.D., professor of cell biology and of medicine and the Diane and Arthur B. Belfer Faculty Scholar in Cancer Research at Einstein and associate chair for translational research in oncology at Montefiore. "Most experimental drugs for leukemia achieve an increase in survival of only a few days in these preclinical models. Even more importantly, ALRN-6924 effectively cured about 40 percent of the treated mice, meaning they were disease free more than one year after treatment--essentially a lifetime for a mouse."

AML is caused by damage to the DNA of blood-forming stem cells in the bone marrow, resulting in abnormal white blood cells, red blood cells, or platelets. About 21,000 people in the U.S. were diagnosed with AML in 2017. Only 27 percent of people diagnosed with AML survive for five or more years, an outcome that has not significantly improved in the past half-century.

ALRN-6924 was developed by Aileron Therapeutics Inc. to target p53, a protein that suppresses tumors but is inactivated in many forms of cancer including AML. The drug was designed to inhibit two naturally occurring proteins, MDMX and MDM2, whose overexpression inactivates p53, allowing cancer cells to multiply unchecked. Aileron turned to Dr. Steidl, an AML expert, to test the drug's effectiveness in preclinical models of AML and to find out more about its mechanism of action.

Dr. Steidl and his colleagues confirmed that ALRN-6924 targets both MDMX and MDM2, blocking their interaction with p53 in AML cells. That effect was seen in both more mature AML cells and the immature stem cells that produce them. "This is important," said Dr. Steidl, "because AML is driven by stem cells--and if you don't target stem cells, the disease will come back very quickly."

Those same molecular changes were observed in blood cells of an AML patient who was given the drug on a compassionate-use basis. "This test was not designed to assess the efficacy of the drug in humans--that has to be done in a proper clinical trial," said Dr. Steidl. "Our goal was to determine whether it can hit the desired target in human cells in a clinical setting, which it did in this individual."

ALRN-6924 is a so-called stapled alpha-helical peptide, a promising new class of drugs whose helical structure is stabilized using hydrocarbon "staples." The stapling prevents the peptides from being degraded by enzymes before reaching their intended target, a fate that often befalls conventional peptide drugs. ALRN-6924 is the first stapled peptide therapeutic to be tested in patients.
-end-
The Montefiore trial is testing ALRN-6924 on patients with relapsed (recurred) or refractory (resistant to treatment) AML or advanced myelodysplastic syndrome (a related condition). The trial is being led by Amit Verma, M.B.B.S., a coauthor on the paper and a professor of medicine and of developmental and molecular biology at Einstein and director of the Myelodysplastic Syndromes Program and of the division of hematologic malignancies at Montefiore Einstein Center for Cancer Care.

Dr. Steidl suspects that the drug may be applicable to other cancers driven by MDMX/MDM2 overexpression and p53 inactivation, including some cases of breast cancer, lung cancer and skin cancers and lymphomas.

The study is titled, "Dual Inhibition of MDMX and MDM2 as a Therapeutic Strategy in Leukemia." Einstein contributors also include Luis A. Carvajal, Ph.D., Daniela Ben Neriah, Adrien Senecal, Ph.D., Lumie Benard, Victor Thiruthuvanathan, Tatyana Yatsenko, Swathi-Rao Narayanagari, M.S., M.D.-Ph.D. student Justin C. Wheat, Tihomira I. Todorova, Ph.D. student Kelly M. Mitchell, Britta Will, Ph.D., Ioannis Mantzaris, M.D., Jesus D. Anampa, M.D., Robert H. Singer, Ph.D., Robert A. Coleman, Ph.D., and M.D.-Ph.D. student Charles Kenworthy. Other authors were Vincent Guerlavais, Ph.D., D. Allen Annis, Ph.D., and Manuel Aivado, M.D., Ph.D., all at Aileron Therapeutics Inc.

This work was supported in part by grants from Aileron Therapeutics Inc. and the National Institutes of Health (NIH) (R01CA166429, R01CA217092, and 5U01EB021236). Information on the clinical trial can be found at clinicaltrials.gov (NCT02909972), a database of clinical studies provided by the NIH.

The authors declare the following competing interests: Drs. Steidl and Carvajal received research funding from Aileron Therapeutics Inc. Drs. Carvajal, Guerlavais, Annis and Aivado are current employees of Aileron.



About Albert Einstein College of Medicine


Albert Einstein College of Medicine is one of the nation's premier centers for research, medical education and clinical investigation. During the 2016-2017 academic year, Einstein is home to 731 M.D. students, 193 Ph.D. students, 106 students in the combined M.D./Ph.D. program, and 278 postdoctoral research fellows. The College of Medicine has more than 1,900 full-time faculty members located on the main campus and at its clinical affiliates. In 2015, Einstein received $148 million in awards from the National Institutes of Health (NIH). This includes the funding of major research centers at Einstein in aging, intellectual development disorders, diabetes, cancer, clinical and translational research, liver disease, and AIDS. Other areas where the College of Medicine is concentrating its efforts include developmental brain research, neuroscience, cardiac disease, and initiatives to reduce and eliminate ethnic and racial health disparities. Its partnership with Montefiore Medical Center, the University Hospital and academic medical center for Einstein, advances clinical and translational research to accelerate the pace at which new discoveries become the treatments and therapies that benefit patients. Through its extensive affiliation network involving Montefiore, Jacobi Medical Center--Einstein's founding hospital, and three other hospital systems in the Bronx, Brooklyn and on Long Island, Einstein runs one of the largest residency and fellowship training programs in the medical and dental professions in the United States. For more information, please visit www.einstein.yu.edu, read our blog, follow us on Twitter, like us on Facebook, and view us on YouTube.

Albert Einstein College of Medicine

Related Stem Cells Articles:

A protein that stem cells require could be a target in killing breast cancer cells
Researchers have identified a protein that must be present in order for mammary stem cells to perform their normal functions.
Approaching a decades-old goal: Making blood stem cells from patients' own cells
Researchers at Boston Children's Hospital have, for the first time, generated blood-forming stem cells in the lab using pluripotent stem cells, which can make virtually every cell type in the body.
New research finds novel method for generating airway cells from stem cells
Researchers have developed a new approach for growing and studying cells they hope one day will lead to curing lung diseases such as cystic fibrosis through 'personalized medicine.'
Mature heart muscle cells created in the laboratory from stem cells
Generating mature and viable heart muscle cells from human or other animal stem cells has proven difficult for biologists.
Mutations in bone cells can drive leukemia in neighboring stem cells
DNA mutations in bone cells that support blood development can drive leukemia formation in nearby blood stem cells.
Scientists take aging cardiac stem cells out of semiretirement to improve stem cell therapy
With age, the chromosomes of our cardiac stem cells compress as they move into a state of safe, semiretirement.
Purest yet liver-like cells generated from induced pluripotent stem cells
A team of researchers from the Medical University of South Carolina and elsewhere has found a better way to purify liver cells made from induced pluripotent stem cells.
Stem cell scientists discover genetic switch to increase supply of stem cells from cord blood
International stem cell scientists, co-led in Canada by Dr. John Dick and in the Netherlands by Dr.
Stem cells from diabetic patients coaxed to become insulin-secreting cells
Signaling a potential new approach to treating diabetes, researchers at Washington University School of Medicine in St.

Related Stem Cells Reading:

Stem Cell Therapy: A Rising Tide: How Stem Cells Are Disrupting Medicine and Transforming Lives
by Neil H Riordan (Author)

Stem cells are the repair cells of your body.  When there aren’t enough of them, or they aren’t working properly, chronic diseases can manifest and persist. From industry leaders, sport stars, and Hollywood icons to thousands of everyday, ordinary people, stem cell therapy has helped when standard medicine failed. Many of them had lost hope. These are their stories.

Neil H Riordan, author of MSC: Clinical Evidence Leading Medicine’s Next Frontier, the definitive textbook on clinical stem cell therapy, brings you an easy-to-read book about how and why stem cells work,... View Details


Stem Cells: Promise and Reality
by Lygia V Pereira (Author)

Stem Cells: Promises and Reality will tell you everything you have always wanted to know about stem cells, but could not understand the field from elsewhere. Stem cells are the great therapeutic promise of the century, and this evolving field of research and medicine brings with it many legal, ethical and psychological issues that must be discussed by society as a whole. Written so as to be accessible to general readers as well as specialists, this book explains what stem cells are, and the different aspects of stem cell research and applications. The book will enable the reader to understand... View Details


Stem Cells: An Insider's Guide
by Paul Knoepfler (Author)

Stem Cells: An Insider's Guide is an exciting new book that takes readers inside the world of stem cells guided by international stem cell expert, Dr. Paul Knoepfler. Stem cells are catalyzing a revolution in medicine. The book also tackles the exciting and hotly debated area of stem cell treatments that are capturing the public's imagination. In the future they may also transform how we age and reproduce. However, there are serious risks and ethical challenges, too. The author's goal with this insider's guide is to give readers the information needed to distinguish between the... View Details


Stem Cell Revolution: Discover 26 Disruptive Technological Advances to Stem Cell Activation
by Joseph Christiano (Author)

Addressing chronic back pain, diabetes, joint replacements, osteoarthritis, neurological issues, and more, Joseph “Dr. Joe” Christiano reveals
how this cutting-edge therapy can rapidly replace damaged cells in the body with no side effects or allergic reactions.
If you have been disappointed by ineffective treatments, the answer to improving your health may be in your stem cells. Dr. Joe explains
how adult stem cell therapy and activators are two of the new technologies in regenerative medicine that will be game changers in medical history.
... View Details


Stem Cells For Dummies
by Lawrence S.B. Goldstein (Author), Meg Schneider (Author)

The first authoritative yet accessible guide to this controversial topic

Stem Cell Research For Dummies offers a balanced, plain-English look at this politically charged topic, cutting away the hype and presenting the facts clearly for you, free from debate. It explains what stem cells are and what they do, the legalities of harvesting them and using them in research, the latest research findings from the U.S. and abroad, and the prospects for medical stem cell therapies in the short and long term.

Explains the differences between adult stem cells and embryonic/umbilical... View Details


The Stem Cell Revolution
by Mark Berman MD (Author), Elliot Lander MD (Contributor)

The book describes the journey into the growing arena of clinical stem cell therapy by highlighting not only the road that brought a team of physicians together but also real stories from a number of their patients that were given their health back through the magic of stem cell therapy. Your fat is loaded with stem cells that can be used now to treat and reverse a large number of inflammatory and degenerative conditions. Most people have no idea that these magical cells actually exist right within our bodies. They think that they must wait until Big Pharma or a university PhD manufactures... View Details


Stem Cells Are Everywhere
by Irv Weissman MD (Author)

An engaging introduction to stem cells for young scientists
 
How do you heal when you cut your skin or break a bone? How does your body keep making new blood or brain cells, or even second teeth? How does a plant keep growing larger? The answers lie in stem cells, which are found in every growing plant and animal. Keeping the subject simple enough for young readers, a pioneer of stem cell research explains cells, tissues, normal growth, what can go wrong, and how to fix it. View Details


A Buyer's Guide to Stem Cell Therapies: Safely Choose the Right Regenerative Treatment for You

The current array of "stem cell" therapies has been called the new wild west of medicine. Between fraudulent advertising and confusing science, it's no wonder that even doctors are unsure of what to think about stem cell treatments. This book aims to educate lay people who may be interested in stem cell or other regenerative treatments as to what options are currently available, both at home and abroad, and what science exists to support their use. View Details


Stem Cells: A Short Course
by Rob Burgess (Author)

Stem Cells: A Short Course is a comprehensive text for students delving into the rapidly evolving discipline of stem cell research. Comprised of eight chapters, the text addresses all of the major facets and disciplines related to stem cell biology and research. A brief history of stem cell research serves as an introduction, followed by coverage of stem cell fundamentals; chapters then explore embryonic and fetal amniotic stem cells, adult stem cells, nuclear reprogramming, and cancer stem cells. The book concludes with chapters on stem cell applications, including the role of stem... View Details


Stem Cells: A Very Short Introduction
by Jonathan Slack (Author)

Embryonic stem cells have been hot-button topics in recent years, generating intense public interest as well as much confusion and misinformation. In this Very Short Introduction, leading authority Jonathan Slack offers a clear and informative overview of stem cells--what they are, what scientists do with them, what stem cell therapies are available today, and how they might be used in the future. Slack explains the difference between embryonic stem cells, which exist only in laboratory cultures, and tissue-specific stem cells, which exist in our bodies, and he discusses how... View Details

Best Science Podcasts 2018

We have hand picked the best science podcasts for 2018. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Turning Kids Into Grown-Ups
Parenting is fraught with uncertainty, changing with each generation. This hour, TED speakers share ideas about raising kids and how — despite our best efforts — we're probably still doing it wrong. Guests include former Stanford dean Julie Lythcott-Haims, former firefighter Caroline Paul, author Peggy Orenstein, psychologist Dr. Aala El-Khani, and poet Sarah Kay.
Now Playing: Science for the People

#470 Information Spookyhighway
This week we take a closer look at a few of the downsides of the modern internet, and some of the security and privacy challenges that are becoming increasingly troublesome. Rachelle Saunders speaks with cyber security expert James Lyne about how modern hacking differs from the hacks of old, and how an internet without national boards makes it tricky to police online crime across jurisdictions. And Bethany Brookshire speaks with David Garcia, a computer scientist at the Complexity Science Hub and the Medical University of Vienna, about the recent Cambridge Analytica scandal, and how social media platforms put a wrench...